Novant Health names new system physician executive for Cancer Institute  

Published 10:49 am Monday, September 27, 2021

Getting your Trinity Audio player ready...
WINSTON-SALEM — Novant Health has named Dr. David Rizzieri as the system physician executive for the Novant Health Cancer Institute.
“We are delighted to welcome Dr. Rizzieri to Novant Health,” said Dr. John Mann, senior vice president of Novant Health institutes. “The Novant Health Cancer Institute strives to be the go-to regional resource for front-line cancer treatment and care. Dr. Rizzieri brings a wealth of experience that I believe will allow us to build on our already strong foundation to provide top-notch comprehensive cancer care to patients across the communities we serve.”
Rizzieri is a medical oncologist and brings more than two decades of experience and leadership to Novant Health, serving most recently at Duke University in Durham, as the clinical vice chief of the hematologic malignancies and cellular therapy division. He has also served as the associate director for clinical research and the founding chief of the section of hematologic malignancies. In addition to his time at Duke University, he is an internationally recognized leader in the field of cancer with more than 200 published articles. He is a member of the Combined International Bone Marrow Transplant Registry Lymphoma Writing Committee and has also served as national chair or co-chair of multiple national lymphoma/leukemia trials with the Alliance for Clinical Trials in Oncology.
Rizzieri completed medical school and residency at the University of Rochester School of Medicine and Dentistry in Rochester, New York, and received fellowship training in hematology and oncology at Duke University.
Novant Health offers world-class cancer care with more than 106 specialty-trained physicians across 51 clinic locations. The Cancer Institute treats more than 100 different types of cancer with an aggressive, leading-edge approach focused on the patient’s physical and emotional needs. Learn more here.
For more information, go to You can also follow Novant on Twitter and Facebook.